This clinical benefit was achieved through IL-1β inhibition pointing toward tissue macrophage-derived elevated IL-1β production as a common denominator for situations with atherosclerosis like type 2 diabetes mellitus, chronic heart failure, and chronic renal disease. This evidence concerns the gene IL1B and atherosclerosis.